Sanofi-Aventis' diet pill failure may force the company to fatten up through a merger with its Plavix marketing partner.
A combination may be the surest way to revive growth at the Paris-based company, which doesn't have a blockbuster to replace the Acomplia obesity drug and may lose a third of its sales to generic competition within five years, analysts said.
Profit is falling and the shares trade at the lowest level in three months.
Sanofi was counting on Acomplia to bring in $3 billion a year.
More at Bloomberg
No comments:
Post a Comment